Inari Medical, Inc. (NARI) Reports Prelim Q4 Revenue of $82.3M-$83.3M

Inari Medical, Inc. (NASDAQ: NARI), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue.

Preliminary Fourth Quarter Highlights:

• Preliminary unaudited revenue is expected to be between $82.8 and $83.3 million for the fourth quarter of 2021, up 14% sequentially and 71% year-over-year (at the midpoint of the range).
• Preliminary unaudited revenue for the full year 2021 is expected to be between $276.6 and $277.1 million, up approximately 98% over the full year 2020.
• Treated 7,700 patients, an increase of 1,000 procedures or 15% from 6,700 procedures completed in Q3. Over 90% of overall procedures and sequential procedural growth came from non-COVID patients.
• Ended 2021 with over 200 U.S. sales territories.

“Despite the challenging operating environment, we are pleased with our continued crisp execution, not only commercially but across all of our growth drivers,” said Bill Hoffman, CEO of Inari Medical. “Although we are humbled by the ongoing opportunity to help treat COVID patients suffering from VTE, we are particularly encouraged that the vast majority of both total procedures and growth during the quarter came from treating non-COVID patients. This core patient population remains our strategic focus. We are increasingly confident we are finding ways to systematically identify, triage, and successfully treat these patients.”

The preliminary unaudited revenue results described in this press release are estimates only and subject to revision until we report our full financial results for 2021 in our Annual Report on Form 10-K.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• PVH Corp. (PVH) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY27 EPS Guidance
• Destination XL Group names Jimmy Olsson as chief growth officer